Wall Street Zen Downgrades Smith & Nephew SNATS (NYSE:SNN) to Buy

Smith & Nephew SNATS (NYSE:SNN) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report released on Saturday.

SNN has been the topic of several other reports. Barclays downgraded Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday. Weiss Ratings lowered Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Finally, Sanford C. Bernstein set a $31.85 price target on Smith & Nephew SNATS in a research report on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Smith & Nephew SNATS currently has a consensus rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Stock Performance

NYSE:SNN opened at $30.10 on Friday. Smith & Nephew SNATS has a 12 month low of $28.56 and a 12 month high of $38.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. The company’s 50 day moving average is $30.46 and its 200-day moving average is $32.12.

Institutional Trading of Smith & Nephew SNATS

A number of hedge funds and other institutional investors have recently made changes to their positions in SNN. Clearstead Trust LLC bought a new stake in Smith & Nephew SNATS during the 2nd quarter worth about $25,000. Garner Asset Management Corp acquired a new position in shares of Smith & Nephew SNATS during the fourth quarter worth approximately $27,000. Arax Advisory Partners lifted its position in shares of Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 569 shares in the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Smith & Nephew SNATS during the fourth quarter valued at approximately $36,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Smith & Nephew SNATS during the third quarter valued at approximately $41,000. 25.64% of the stock is currently owned by institutional investors and hedge funds.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.